Evidence map›Paper›PMID 23954313›Full record

ReviewGastroenterology2013

Impaired emotional learning and involvement of the corticotropin-releasing factor signaling system in patients with irritable bowel syndrome.

Jennifer S Labus, Catherine S Hubbard, Joshua Bueller, Bahar Ebrat, Kirsten Tillisch, Michelle Chen, Jean Stains, George E Dukes, Dennis L Kelleher, Bruce D Naliboff and 2 more

Abstract readReview
In one paragraph

Review in Gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jennifer S LabusGail and Gerald Oppenheimer Family Center for the Neurobiology of Stress, University of California, Los Angeles, Los Angeles, California; Department of Medicine, University of California, Los Angeles, Los Angeles, California; Department of Psychiatry, University of California, Los Angeles, Los Angeles, California.
Catherine S Hubbard
Joshua Bueller
Bahar Ebrat
Kirsten Tillisch
Michelle Chen
Jean Stains
George E Dukes
Dennis L Kelleher
Bruce D Naliboff
Michael Fanselow
Emeran A Mayer
University of California, Los Angeles · USGlaxoSmithKline (United States) · USBrain Mapping Foundation · USVA Greater Los Angeles Healthcare System · US

Funding

Women's Health and Functional Visceral Disorders CenterP50DK064539 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAYER, EMERAN A · 2002 to 2017
$17.5M
GASTROENTEROLOGYT32DK007180 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JENSEN, DENNIS MICHAEL · 1986 to 2025
$10.0M
PERCEPTION AND MODULATION OF VISCERAL SENSATIONSR01DK048351 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAYER, EMERAN A · 1996 to 2019
$8.2M
Central and Peripheral Autonomic Responses in Irritable Bowel SyndromeK23DK073451 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TILLISCH, KIRSTEN · 2006 to 2010
$625k
Effective connectivity of central response to Irritable Bowel Syndrome (IBS)K08DK071626 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LABUS, JENNIFER S · 2006 to 2010
$607k
NIDDK NIH HHS K08 DK071626NIDDK NIH HHS K23 DK073451NIDDK NIH HHS P50 DK064539NIDDK NIH HHS R01 DK048351NIDDK NIH HHS T32 DK007180NIDDK NIH HHS T32 DK07180-34
6 · The paper itself

Abstract

BACKGROUND &

aimsAlterations in central corticotropin-releasing factor signaling pathways have been implicated in the pathophysiology of anxiety disorders and irritable bowel syndrome (IBS). We aimed to characterize the effects of the corticotropin-releasing factor receptor 1 (CRF-R1) antagonist, GW876008, on brain and skin conductance responses during acquisition and extinction of conditioned fear to the threat of abdominal pain in subjects with IBS and healthy individuals (controls).

methodsWe performed a single-center, randomized, double-blind, 3-period crossover study of 11 women with IBS (35.50 ± 12.48 years old) and 15 healthy women (controls) given a single oral dose (20 mg or 200 mg) of the CRF-R1 antagonist or placebo. Blood-oxygen level-dependent responses were analyzed using functional magnetic resonance imaging in a tertiary care setting.

resultsControls had greater skin conductance responses during acquisition than extinction, validating the fear-conditioning paradigm. In contrast, during extinction, women with IBS had greater skin conductance responses than controls-an effect normalized by administration of a CRF-R1 antagonist. Although the antagonist significantly reduced activity in the thalamus in patients with IBS and controls during acquisition, the drug produced greater suppression of blood-oxygen level-dependent activity in a wide range of brain regions in IBS patients during extinction, including the medial prefrontal cortex, pons, hippocampus, and anterior insula.

conclusionsAlthough CRF signaling via CRF-R1 is involved in fear acquisition and extinction learning related to expected abdominal pain in patients with IBS and controls, this system appears to be up-regulated in patients with IBS. This up-regulation might contribute to the previously reported abnormal brain responses to expected abdominal pain.

Indexed as

Abdominal PainAdultAnxiety DisordersBrainBrain MappingBridged Bicyclo Compounds, HeterocyclicCorticotropin-Releasing HormoneCRF Receptor, Type 1Cross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodExtinction, PsychologicalFearFemaleGalvanic Skin ResponseHumansBridged Bicyclo Compounds, HeterocyclicCorticotropin-Releasing HormoneCRF Receptor, Type 1GW 876008PyrazolesReceptors, Corticotropin-Releasing HormoneaINSaMCCAMYGamygdalaanterior insulaanterior midcingulate cortexblood-oxygen level−dependentBOLDcorticotropin-releasing factor receptor 1Corticotropin-Releasing Factor Receptor 1 (CRF-R1) AntagonistCRF-R1dlPFCdorsolateral prefrontal cortexExtinctionFear ConditioningHCshealthy controlsHIPPhippocampusHYPOhypothalamusIBSirritable bowel syndromeLCClocus coeruleus complexmedial prefrontal cortexmPFCpACCPLAplacebopregenual anterior cingulate cortexSCRskin conductance responsesSNSsympathetic nervous systemTHALthalamusventrolateral prefrontal cortexvlPFC

Identifiers

PMID23954313
PMCPMC4069031
OpenAlexW2091338428

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.